Chinook Therapeutics CVR
13F holders, Q4 2024 (December 31)6holders +2
2new positions
0sold out
$0.24avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Chinook Therapeutics CVR in their 13F filings, up 2 from Q3 2024. 2 opened new positions and 0 sold out. The largest holders were Erste Asset Management GmbH ($120K), Propel Bio Management, LLC ($10K) and Public Employees Retirement System of Ohio ($6).
- Company
- Chinook Therapeutics CVR
- CUSIP
- 169CVR016
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $6 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 61,357 shares bought, net +61,357 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Erste Asset Management GmbH | 0.00% | No change | 307,769 | $120K |
| Propel Bio Management, LLC | 0.01% | No change | 79,357 | $10K |
| Public Employees Retirement System of Ohio | 0.00% | New | 60,000 | $6 |
| Bessemer Group Inc. | 0.00% | New | 50 | $0 |
| Rhumbline Advisers | 0.00% | Add +1.5% | 90,726 | $0 |
| Sterling Capital Management LLC | 0.00% | No change | 1,053 | $0 |
"% of holder's portfolio" is CHINOOK THERAPEUTICS CVR's weight in each manager's 13F, not the share of Chinook Therapeutics CVR the manager owns.